PEBBLE LABS
DEAD

Serial Number

88225549

Owner

PEBBLE LABS INC.

Attorney

David S. Kerr

First Use Date

Jan 7, 2018

Filing Date

Dec 11, 2018

Add to watchlist:

No watchlists yet
View on USPTO

PEBBLE LABS Trademark

Serial Number: 88225549 • Registration: 5819332

PEBBLE LABS is a trademark filed by PEBBLE LABS INC. on December 11, 2018. The trademark is classified under Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

PEBBLE LABS INC. (9 trademarks)

433 PASEO DE PERALTA
SANTA FE, NM 87501

Entity Type: 03

PEBBLE LABS, INC.

100 ENTRADA DR
LOS ALAMOS, NM 87544

Entity Type: 03

Pebble Labs Inc.

100 Entrada Drive
Los Alamos, NM 87544

Entity Type: 03

Trademark Details

Filing Date

December 11, 2018

Registration Date

July 30, 2019

First Use Anywhere

January 7, 2018

First Use in Commerce

January 7, 2018

Published for Opposition

May 14, 2019

Cancellation Date

February 13, 2026

Goods & Services

Medical research and development in the field of synthetic biology, molecular biology, genetic engineering and bioinformatics; Design and development of biological RNA-based therapeutic agents for the prevention and treatment of infectious diseases in plants and animals for use in pharmaceuticals, biotechnology, and medical and diagnostic applications; Research and development of biopharmaceutical compounds; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of target pathogen genes in plants and animals; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit vector-borne diseases; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit aquaculture-related diseases; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit mosquito populations; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit bacterial quorum-sensing; Research and development of genetically engineered organisms; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit the expression of target genes; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit the expression of target pathogen genes in plants and animals; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit vector-borne diseases; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit aquaculture-related diseases; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit mosquito populations; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit bacterial quorum-sensing; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce that produce eukaryotic-like mRNA; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce that produce commercial compounds; Research and development of genetically engineered organisms, namely, genetically engineered algae that produce that produce waxes; Research and development of pharmaceuticals, therapeutics, and biologics; Research and development of new biological products for therapeutic use

Filing History

CANCELLED SEC. 8 (6-YR)
Feb 13, 2026 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jul 30, 2024 REM1
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jan 6, 2021 ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Oct 9, 2019 ASGN
REGISTERED-PRINCIPAL REGISTER
Jul 30, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 14, 2019 NPUB
PUBLISHED FOR OPPOSITION
May 14, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 24, 2019 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Apr 10, 2019 PREV
ASSIGNED TO LIE
Apr 5, 2019 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 14, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 14, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 14, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 14, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 14, 2019 CNEA
ASSIGNED TO EXAMINER
Mar 8, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 3, 2019 NWOS
NEW APPLICATION ENTERED
Dec 14, 2018 NWAP